Effective treatment of painful bone crises in type I gaucher's disease with high dose prednisolone
- PMID: 8976661
- PMCID: PMC1511695
- DOI: 10.1136/adc.75.3.218
Effective treatment of painful bone crises in type I gaucher's disease with high dose prednisolone
Abstract
In type I Gaucher's disease, episodes of severe disabling bone pain, the so called bone crises, may be resistant to all analgesics, including narcotics. The demonstration of subperiosteal oedema on magnetic resonance imaging (MRI) led to an attempt to use steroids to relieve the oedema and thereby the pain. On eight occasions, five patients with documented bone crises received conventional dose steroids (20 mg/m2/day) with considerable shortening of the attacks. On six occasions five further patients received high dose methylprednisolone (30 mg/kg intravenously or 1 g/m2 orally daily for two days), which was followed by oral prednisone for three to five days on the last four occasions. In this later group, pain relief was evident within several hours. Three treatments were given on an ambulatory basis. The MRI scan of one of these patients showed no subperiosteal fluid collection five days after high dose steroids had been started, and on subsequent x ray examination, there was no periosteal elevation. This treatment should be considered in cases of Gaucher's disease with bone crises.
Similar articles
-
Hemorrhage associated with "bone crisis" in Gaucher's disease identified by magnetic resonance imaging.Skeletal Radiol. 1991;20(7):479-82. doi: 10.1007/BF00194240. Skeletal Radiol. 1991. PMID: 1754907
-
Commentary: low-dose high-frequency enzyme replacement therapy prevents fractures without complete suppression of painful bone crises in patients with severe juvenile onset type I Gaucher disease.Blood Cells Mol Dis. 1998 Sep;24(3):303-5; discussion 306-8. doi: 10.1006/bcmd.1998.0196. Blood Cells Mol Dis. 1998. PMID: 10087988 No abstract available.
-
Aminohydroxy propylidene bisphosphonate (APD) treatment improves the clinical skeletal manifestations of Gaucher's disease.Pediatrics. 1994 Sep;94(3):385-9. Pediatrics. 1994. PMID: 8065868
-
[Bone manifestations of Gaucher's disease in Mexican patients].Acta Ortop Mex. 2010 Sep-Oct;24(5):351-8. Acta Ortop Mex. 2010. PMID: 21246808 Review. Spanish.
-
[Pyogenic osteomyelitis in Gaucher's disease].Rev Med Interne. 1992 Jul-Aug;13(4):289-92. doi: 10.1016/s0248-8663(05)80303-0. Rev Med Interne. 1992. PMID: 1287770 Review. French.
Cited by
-
Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring.Eur J Pediatr. 2004 Feb;163(2):67-75. doi: 10.1007/s00431-003-1363-z. Epub 2003 Dec 16. Eur J Pediatr. 2004. PMID: 14677062 Review.
-
Gaucher disease: the metabolic defect, pathophysiology, phenotypes and natural history.Pediatr Endocrinol Rev. 2014 Sep;12 Suppl 1(0 1):72-81. Pediatr Endocrinol Rev. 2014. PMID: 25345088 Free PMC article. Review.
-
Lysosomal storage disease overview.Ann Transl Med. 2018 Dec;6(24):476. doi: 10.21037/atm.2018.11.39. Ann Transl Med. 2018. PMID: 30740407 Free PMC article. Review.
-
Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements.Eur J Pediatr. 2004 Feb;163(2):58-66. doi: 10.1007/s00431-003-1362-0. Epub 2003 Dec 16. Eur J Pediatr. 2004. PMID: 14677061 Review.
-
Revised recommendations for the management of Gaucher disease in children.Eur J Pediatr. 2013 Apr;172(4):447-58. doi: 10.1007/s00431-012-1771-z. Epub 2012 Jul 8. Eur J Pediatr. 2013. PMID: 22772880 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical